Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rachel Moate"'
Autor:
Tom Wilkinson, Anthony De Soyza, Miles Carroll, James D. Chalmers, Michael G. Crooks, Gareth Griffiths, Manu Shankar-Hari, Ling-Pei Ho, Alex Horsley, Chris Kell, Beatriz Lara, Biswa Mishra, Rachel Moate, Clive Page, Hitesh Pandya, Jason Raw, Fred Reid, Dinesh Saralaya, Ian C. Scott, Salman Siddiqui, Andy Ustianowski, Natalie van Zuydam, Ashley Woodcock, Dave Singh
Publikováno v:
ERJ Open Research, Vol 9, Iss 5 (2023)
Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving ou
Externí odkaz:
https://doaj.org/article/663594df92f142cd8da36d4a4738c12b
Autor:
Isharat Yusuf, Stacey Drabic, Albulescu Marius, Melissa de los Reyes, Rachel Ettinger, Manuel Baca, Jodi L. Karnell, Li Yan, Ximing Xiong, Thomas Thisted, L. Wang, Ulf Müller-Ladner, David Howe, Jing Li, Jorn Drappa, Steven Eck, Rachel Moate, Ronald Herbst, Michele Gunsior, Katie Streicher, Vaheh Oganesyan
Publikováno v:
Science Translational Medicine. 11
The CD40/CD40L axis plays a central role in the generation of humoral immune responses and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the generation and clinical results of a CD40L binding protein, VIB4920
Autor:
Andreas Wollenberg, Koustubh Ranade, Jonathan I. Silverberg, Rachel Moate, Emma Guttman-Yassky, Michael D. Howell, René van der Merwe, Christopher Kell
Publikováno v:
The Journal of allergy and clinical immunology. 143(1)
Background IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. Objective We sought to evaluate the efficacy and safety of tralokinumab in adults with
Autor:
Stefano Zamuner, Ole Graff, Susan Marie Learned, Gary Evoniuk, Suraja Roychowdhury, Jack G. Modell, Rachel Moate, Emiliangelo Ratti, Robert L. Alexander, Graeme Archer, K. Ranga Rama Krishnan, Agnes Lavergne
Publikováno v:
Journal of Psychopharmacology. 26:653-662
GSK372475 is a triple reuptake inhibitor with approximately equipotent inhibition of serotonin, norepinephrine, and dopamine transporters. Two randomized, placebo- and active-controlled, double-blind studies examined the efficacy and safety of GSK372